STAMFORD, Conn. – September 24, 2018 – Marcelo E. Bigal MD, Ph.D. Chief Medical Officer, Purdue Pharma L.P., issued the following statement today: The nation’s opioid crisis is a significant and urgent public health challenge, and Purdue Pharma is...
News and Media Purdue Pharma L.P. and Geisinger Present Interim Analysis fromWearable Health Technology Clinical Trial at PAINWeek® 2018 Annual Conference Results Show Successful Uptake of Technology and Increased Patient‐Provider Communication STAMFORD, Conn., and...
News and Media Purdue Pharma L.P. to Present Data from Three Research Studies atPAINWeek® 2018 Annual Conference Studies Underscore Company’s Ongoing Commitment to Working Collaboratively onMeaningful Solutions to Address the Opioid Crisis STAMFORD, Conn., September...
STAMFORD, Conn. and PITTSBURGH, Penn., September 5, 2018 – Purdue Pharma L.P. (Purdue) and Harm Reduction Therapeutics, Inc. today announced that Purdue is providing a $3.42 million grant to Harm Reduction Therapeutics to advance the...
Please read carefully the Purdue Pharma L.P. Privacy Policy (the “Privacy Policy”), which is part of the Purdue Pharma L.P. Terms and Conditions, before you access, download, or otherwise use any of our websites, related other parities’ websites, mobile applications, or any electronic service (collectively, the “Service”). This Privacy Policy describes the information collected through Your use of the Service, how we use it, how we share it, how we protect it, and the choices You can make about Your information.
